Drugs / DAR-901
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02063555 | Feb 2014 → Mar 2016 | tuberculosis | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00052195 | Sep 2001 → Dec 2008 | HIV infectious disease, tuberculosis | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02712424 Comparator | Mar 2016 → Feb 2020 | tuberculosis | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DAR 901 | “This is a Phase 1, randomized, controlled, double-blind, multiple-dose, dose-ranging study of DAR 901, (an inactivated whole cell mycobacterial vaccine) to be conducted in HIV...” NCT02063555 ↗ |
| Known as | SRL-172 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00052195 ↗ |
| Modality | Vaccine | “DAR-901 is an inactivated whole cell tuberculosis booster vaccine” PMID 31120957 ↗ May 2019 |